Text size:

• normal
• large

• Get involved
• Donations
• Membership
• Fundraising
• Volunteering
• Consider leaving a gift in your will
• Campaigning / Influencing
  • National Campaigning
    • National Service Framework for Long-Term Conditions
    • Assisted Dying For the Terminally Ill Bill
    • All-Party Parliamentary Group on MND
    • NICE appraisal of riluzole
    • Welfare Reform Green Paper
    • AA/DLA Information Bill
    • Mental Capacity Act 2005
    • Equipment Provision
    • End of Life Care Strategy/ Board
    • Disabled Facilities Grants
  • Guide to Influencing for Branches and Groups
• Tribute Funds
• Grant-Making Trusts and Foundations

In January 2001 the National Institute for Health and Clinical Excellence (NICE) published its guidance on the use of the drug riluzole (Rilutek) in the treatment of Motor Neurone Disease (MND).

NICE recommended that riluzole be prescribed to individuals with the amyotrophic lateral sclerosis (ALS) form of MND.  (The term ALS is used interchangeably with MND in the UK).

View a copy of the NICE guidance on riluzole

View a copy of the patient leaflet on the NICE guidance

The MND Association submitted evidence to NICE during the appraisal of riluzole. 

Read the MND Association submission to NICE (211 kb)

Further information

For further information please contact the Public Affairs Team on 01604 611842.

• View a full copy of the NICE guidance
• View a copy of the patient leaflet

• Back to top
• Print page
• Send to a friend

• Research into Treatments for MND
• What Is MND - Treatments